EYLEA (aflibercept), anti-VEGF
OPHTHALMOLOGY - New indication
Opinions on drugs - Posted on Jan 25 2016
Reason for request
Extension of inclusion
Minor improvement in the management of visual impairment secondary to branch retinal vein occlusion.
- EYLEA now has Marketing Authorisation in the treatment of visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO).
- Its efficacy has been demonstrated versus laser photocoagulation but it has not been compared with LUCENTIS or OZURDEX.
- Like LUCENTIS, it is a first-line treatment that provides minor clinical added value in the management of visual impairment secondary to BRVO.
Clinical Added Value
Évaluation des médicaments